Status:
COMPLETED
Efficacy and Safety of XP12B in Women With Menorrhagia
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Menorrhagia
Heavy Menstrual Bleeding
Eligibility:
FEMALE
18-49 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
Eligibility Criteria
Inclusion
- Women with menorrhagia
- 18-49 years of age
- Regularly occurring menstrual periods
Exclusion
- History or presence of clinically significant disease or abnormalities that may confound the study
- History of bilateral oophorectomy or hysterectomy
- Hormone therapy for birth control
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
304 Patients enrolled
Trial Details
Trial ID
NCT00401193
Start Date
November 1 2006
End Date
May 1 2008
Last Update
May 13 2015
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Birmingham, Alabama, United States, 35209
2
Investigative Site
Phoenix, Arizona, United States, 85015
3
Investigative Site
Tucson, Arizona, United States, 85710
4
Investigative Site
Tucson, Arizona, United States, 85712